The Immunotherapy Roadmap.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26459176.
- Also identified by DOI 10.1158/1078-0432.CCR-15-2144 and PMC identifier 4715971.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations.
Medical subject headings
- Immunotherapy
- Neoplasms